REVENUE-SHARE TELEHEALTH PLATFORM
Tessic vs OpenLoop
OpenLoop rents a brand a telehealth clinic, then keeps 50 to 59 percent of every maintenance patient's payment, indefinitely, while owning the merchant account, the card tokens, and the patient data. Tessic Health charges flat published fees, marks up nothing, and leaves the client owning the patients, the records, and the data. Here is the line-by-line math.
$25
Flat per completed consult
0%
Medication markup
0%
Revenue share, on every plan
50
States with licensed providers
01
Side-by-side scorecard
Every Tessic Health cell is a published term. Every OpenLoop cell comes from its own written proposal or a public source.
| Criterion | Tessic Health | OpenLoop |
|---|---|---|
| Upfront cost (with LegitScript) | $8,000 (Launch); LegitScript application filed as part of setup | $12,000 |
| Monthly fee | $1,000 flat on Launch, month to month | $1,500 from first patient |
| Contract | Month to month, cancel any time | 12-month term |
| Medication pricing | Wholesale pass-through, 0% markup | Bundled into 42 to 59% revenue retention |
| Consultation pricing | $25 flat per completed consult | Bundled into retention |
| Per-patient fees | None; no revenue share | Effectively 50 to 59% of maintenance revenue |
| Billing relationship and card tokens | The client owns the billing relationship | OpenLoop owns the merchant account and the card tokens |
| Patient record ownership | The client; records leave with the client | OpenLoop's systems |
| Cash flow | The brand bills its own patients; no remittance | Weekly remittance from OpenLoop |
| Pharmacy | Tessic's wholesale pharmacy with cold-chain delivery | OpenLoop supply chain only |
| Providers | Licensed in all 50 states, credentialed under the client's brand | OpenLoop providers only |
| Exit and migration | Cancel any month with patients, records, and data | Effectively a business reset |
| Data breach history | n/a | 716K patients, January 2026, HHS-confirmed |
| Employer ratings (service-quality proxy) | n/a | Glassdoor 2.8, Indeed 2.4 |
| 50-state coverage | Yes, all 50 states | Yes (all 50 + DC) |
| Amex acceptance | The brand's decision | Not accepted |
02
The short version
Prepared July 2026, based on OpenLoop's own written proposal (expiring May 28, 2026), Tessic Health's published commercial terms, and publicly verifiable third-party sources. Shipping costs are excluded from all calculations.
03
Executive summary
OpenLoop and Tessic Health both offer white label telehealth: clinicians, EHR, e-prescribing, pharmacy fulfillment, and compliance behind a client's brand. The similarity ends there. The two operate on opposite business models.
OpenLoop is a revenue-share landlord. Patients pay into OpenLoop's merchant account. OpenLoop owns the billing relationship, the credit card tokens, and the patient data pipeline, then remits a "Membership Services Fee" back to the clinic weekly. On maintenance patients, OpenLoop retains 50 to 59 percent of every dollar the patient pays, on every patient, for as long as the patient stays.
Tessic Health is a flat-fee utility. The brand bills its own patients. Tessic passes medication through at 0% markup, charges a flat $25 per completed consult, and takes no per-patient cut and no revenue share. The brand keeps retail price minus wholesale medication cost minus the $25 consult, so its margin scales with it; Tessic's revenue does not grow when the client's does. And because the client owns the patients, records, and data, leaving is a decision rather than a rebuild. Add a January 2026 data breach affecting about 716,000 downstream patients and sub-3-star employer ratings on Glassdoor and Indeed, and the picture is clear.
04
Business model and money flow
| Tessic Health | OpenLoop | |
|---|---|---|
| Who charges the patient | The brand, through its own branded storefront and patient portal | OpenLoop: the patient's card is charged into OpenLoop's merchant account |
| Who owns the billing relationship | The client. Tessic takes no cut of revenue or patients | OpenLoop ("merchant account management... is OpenLoop's responsibility") |
| Who owns the credit card tokens | The client owns the billing relationship | OpenLoop |
| Who owns patient records | The client; records and data leave with the client at any time | OpenLoop's EHR holds patient processing; data lives in their system |
| When the brand gets paid | The brand bills its own patients; there is no remittance from Tessic because Tessic takes no share of the revenue | Weekly remittance: "every Wednesday for the week ending Tuesday," calculated by OpenLoop from their count of net active patients |
| Revenue model | Flat fees only: a monthly platform fee, $25 per completed consult, 0% medication markup, no per-patient fee, no revenue share | Retains the spread between what the patient pays and what they remit to the clinic (typically 42 to 59% of patient revenue) |
| Pricing freedom | The brand sets its own retail prices; the margin above wholesale medication cost and the $25 consult is the brand's | Retail prices and the remittance are fixed in OpenLoop's schedule; changing the economics means renegotiating with OpenLoop |
| Payment methods | The brand's decision, since the client owns the billing relationship | Visa, MC, FSA/HSA, Apple Pay, Google Pay, but no American Express |
05
Why this matters more than any single fee
On OpenLoop, the clinic's entire revenue stream, every card token, every subscription billing record, and every patient chart, lives inside OpenLoop's systems. Migrating away means re-acquiring payment authorization from every patient and rebuilding billing from zero. That is functionally a customer-base reset, and it is the quiet mechanism that keeps clinics locked in regardless of how the relationship goes. On Tessic Health, the client owns the brand, the patients, the records, and the data from the first day, and can cancel any month with all of it intact.
06
Fixed costs and contract terms
| Tessic Health | OpenLoop | |
|---|---|---|
| Setup / implementation fee | $8,000 (Launch plan) | $9,000 ($4,500 at signing, $4,500 at first patient) |
| LegitScript certification | Application prepared and filed by Tessic as part of setup; certification is never guaranteed, since LegitScript sets its own schedule | +$3,000 flat fee (optional add-on, expedited) |
| Effective upfront cost with LegitScript | $8,000 | $12,000 |
| Monthly platform fee | $1,000 flat on Launch, month to month | $1,500/mo from first patient seen |
| Contract commitment | Month to month. No term. Cancel any time | 12-month initial term |
| Adding new business lines | Every treatment vertical is included on every plan | Requires an MSA addendum plus a separate implementation fee |
| Year-1 fixed outlay | $20,000 ($8,000 + $1,000 x 12) | $30,000 ($9,000 + $3,000 LegitScript + $1,500 x 12) |
| Year-2+ fixed outlay | $12,000/yr | $18,000/yr |
07
Comparison basis
Tessic Health figures use the Launch plan, the entry tier at $1,000 a month with an $8,000 setup, because it is the tier that matches OpenLoop's single quoted rate. Tessic also publishes Grow at $2,000 a month ($15,000 setup), Scale at $4,000 a month ($25,000 setup), and Tessic Prescribe at custom pricing for a brand with its own EHR; every plan carries identical commercial terms (month to month, $25 consults, 0% medication markup, no revenue share). Whichever plan a brand picks, the fixed-fee gap is the smaller half of this comparison: the per-patient economics below dwarf it at any real patient count.
08
What the fixed costs add up to
Year one on OpenLoop runs $30,000 in fixed fees, contractually locked for 12 months, versus $20,000 on Tessic Health's Launch plan with no commitment: a $10,000 (33%) difference before a single patient-level dollar is counted. The gap persists at steady state ($12,000 a year versus $18,000 a year). Tessic's upfront is $4,000 lower once OpenLoop's LegitScript add-on is included, and every treatment vertical is included on every Tessic plan rather than arriving as an addendum with its own implementation fee. If a launch stalls, a funnel underperforms, or the brand simply wants to change direction, OpenLoop holds it to the term; Tessic lets it cancel any month.
09
Per-patient economics: where the real money is
OpenLoop's proposal is transparent about its mechanism: one column is what the patient pays, the next is what the clinic receives, and "the difference... is what is retained by OpenLoop." The tables below reproduce OpenLoop's own price points and remittances, with the retained share computed from those two numbers.
On Tessic Health the same patient's economics have a different shape. The brand sets the retail price and bills the patient. Its cost per patient is the wholesale medication price passed through at 0% markup plus $25 per completed consult, in month one and again whenever the clinical protocol calls for a follow-up consult. There is no percentage retained by Tessic at any month. Tessic publishes wholesale medication pricing to clients rather than on this page, so no Tessic-side per-patient dollar figure is stated here; the brand can compute it as retail minus wholesale minus $25.
10
Semaglutide injection on OpenLoop: $249 a month retail
| Month | Patient pays | Brand receives on OpenLoop | OpenLoop retains |
|---|---|---|---|
| Month 1 (with consult) | $249 | $140 | $109 (44%) |
| Month 5+ (maintenance) | $249 | $124 | $125 (50%) |
| 12-month patient value | $2,988 | $1,514 | $1,474 (49%) |
Patient-pays and brand-receives figures are OpenLoop's own proposal numbers; the retained column is the difference. Shipping excluded.
11
Tirzepatide injection on OpenLoop: $339 a month retail
| Month | Patient pays | Brand receives on OpenLoop | OpenLoop retains |
|---|---|---|---|
| Month 1 | $339 | $196 | $143 (42%) |
| Month 5+ (maintenance) | $339 | $138 | $201 (59%) |
OpenLoop's own proposal numbers; the retained column is the difference. Shipping excluded.
12
What the tirzepatide line shows
On OpenLoop's tirzepatide maintenance line, the patient pays $339 and the clinic receives $138. OpenLoop keeps $201, or 59% of the patient's payment, every month the patient stays. On Tessic Health, that same $339 is the brand's, less the wholesale cost of the medication at the patient's dose and the $25 consult when one occurs, with nothing retained as a percentage.
13
Semaglutide oral ODT on OpenLoop: $279 a month retail
| Month | Patient pays | Brand receives on OpenLoop | OpenLoop retains |
|---|---|---|---|
| Month 1 | $279 | $136 | $143 (51%) |
| Month 5+ | $279 | $128 | $151 (54%) |
OpenLoop's own proposal numbers; the retained column is the difference. Shipping excluded.
14
The prepay penalty on long commitments
OpenLoop's long-commitment tiers compound the problem. On the 52-week semaglutide injection plan, the patient pays $2,327 and the clinic receives $1,076, so OpenLoop retains $1,251 (54%) of a patient who committed to the brand for a year. On the 52-week tirzepatide plan, the patient pays $3,497 on day one and the clinic's share is $1,572, so OpenLoop retains $1,925 (55%). On Tessic Health, a 52-week prepaid patient is billed by the brand at whatever annual price the brand sets, and the brand's cost for that year is the wholesale medication plus the consults that occur, with no share of the prepayment retained by Tessic.
15
Scale math: what OpenLoop retains on maintenance patients
OpenLoop's retained share on maintenance patients, annualized at different patient counts, using OpenLoop's own month 5+ figures ($125 a month on semaglutide injection at $249 retail, $201 a month on tirzepatide at $339 retail).
| Maintenance patients | Retained by OpenLoop per year (semaglutide injection) | Retained by OpenLoop per year (tirzepatide) |
|---|---|---|
| 100 | $150,000 | $241,200 |
| 500 | $750,000 | $1,206,000 |
| 1,000 | $1,500,000 | $2,412,000 |
OpenLoop's retained share bundles medication cost, consults, base labs, billing, and patient support (see the fairness note). On Tessic Health the equivalent per-patient cost is the wholesale medication price at 0% markup plus $25 per completed consult, with no percentage retained; the platform fee is flat at every patient count.
16
What the scale math means
The fixed-fee difference between the platforms is rounding error next to this. OpenLoop's model taxes the clinic's growth; Tessic Health's flat fee does not move when patient count does.
17
Flexibility and vendor independence
| Tessic Health | OpenLoop | |
|---|---|---|
| Pharmacy network | Tessic's wholesale pharmacy at 0% markup with cold-chain delivery; Tessic makes no margin on medication | OpenLoop's supply chain only; fulfillment and medication costs run through them |
| Provider network | Licensed providers in all 50 states, credentialed under the client's brand and managed by Tessic | OpenLoop-recruited and credentialed providers on their platform |
| Care model control | The brand's programs, under the brand's name, with clinical decisions sitting with the licensed clinicians under the friendly-PC structure; every vertical included on every plan | Defined in OpenLoop's schedules (consult cadence, age limits, program structure); "availability of any given GLP-1 option may change at any time, with no notice" |
| Exit path | Cancel any month; patients, records, and data leave with the client | 12-month term; patient billing, tokens, and records live in OpenLoop's systems |
18
The structural point
Because Tessic Health makes no margin on medication and charges a flat $25 per consult, it has no conflict of interest in how the brand grows or where it goes. OpenLoop's economics depend on being the toll booth between the clinic and its patients.
19
The January 2026 data breach: 716,000 patients exposed
This is confirmed on the HHS Office for Civil Rights breach portal and was reported to the California and Texas Attorneys General. On January 7, 2026, an unauthorized third party accessed OpenLoop's systems and exfiltrated files containing patient names, addresses, email addresses, dates of birth, and medical information, affecting up to 716,000 individuals across the telehealth brands running on OpenLoop's platform. A threat actor ("Stuckin2019") publicly claimed 1.6 million records and posted samples as proof. The affected population "spans patients across multiple client organizations rather than direct OpenLoop consumers," meaning it was OpenLoop's clients' patients, under their clients' brand names, whose data was stolen.
For a clinic evaluating OpenLoop, the lesson is architectural as well as reputational. OpenLoop's model concentrates 120+ brands' worth of patient data in one place. When it was breached, every downstream clinic inherited the incident, the notification obligations, the patient trust damage, and the churn, for a security failure it had no control over. On Tessic Health's model, the client owns its patient records, under a HIPAA Business Associate Agreement for every client, with SOC 2 Type II, SSO, and audit logs on the Scale plan.
20
The Google reviews and what they measure
OpenLoop shows 1,197 Google reviews averaging 4.5 stars. Read them and the pattern is clear: the reviews are overwhelmingly from patients of client clinics ("clinician was very attentive," "how fast my order was delivered by FedEx," "waiting on my prescription"), not from clinic operators evaluating OpenLoop as a B2B vendor. That makes the rating unusable as a B2B signal. A patient's five-star FedEx delivery experience says nothing about how OpenLoop treats the clinics that are its actual customers.
21
What OpenLoop's own staff say
The B2B-relevant public signals point the other way from the Google rating.
| Source | Rating | Detail |
|---|---|---|
| Glassdoor | 2.8 / 5 | Only 33% would recommend to a friend; 37% approve of the CEO; 45% positive business outlook (100 reviews) |
| Indeed | 2.4 / 5 | 51 reviews; heavily 1-star-weighted distribution; job security and advancement rated 1.9; reviewers flag lack of "trust in colleagues" (updated May 31, 2026) |
Glassdoor and Indeed company pages as of May 2026.
22
Why employer ratings matter to a client
Employee reviews are not client reviews, but they are a leading indicator of service quality. A company whose own staff rate job security at 1.9 out of 5, and where barely a third would recommend working there, is a company with turnover and morale problems, and turnover in credentialing, support, and account management lands directly on clients. The 4.5-star Google rating and the 2.4 to 2.8 employer ratings describe two different companies.
23
Fifteen red flags inside OpenLoop's own proposal
The items below come from an actual OpenLoop proposal, a "Summary of Proposed Services" prepared for a prospective clinic, complete with pricing schedules, program terms, and contract structure, read line by line. Nothing here is paraphrased from marketing or hearsay. Read individually, each item is a concession; read together, they describe a contract in which risk flows to the client and margin flows to OpenLoop.
01
The maturity penalty: OpenLoop's cut grows the longer a patient stays. On tirzepatide, the patient pays the same $339 every month, but the clinic's remittance falls from $196 in month 1 to $138 at month 5+, while OpenLoop's take climbs from $143 (42%) to $201 (59%). That is a 41% increase in OpenLoop's cut and a 30% drop in the clinic's revenue on the identical patient paying the identical price. Retention is the hardest thing to earn in telehealth; this schedule sends the fruits of the clinic's retention to OpenLoop.
02
The clinic funds the patient discounts on long-term plans. On the 52-week semaglutide plan, the patient's price drops 28% (from $249 to $179 per cycle), but the clinic's remittance drops 33% (from $124 to about $83 per cycle). OpenLoop offers the patient a discount and makes the clinic absorb a disproportionate share of it.
03
OpenLoop holds the float on annual prepayments. A 52-week tirzepatide patient pays $3,497 on day one, into OpenLoop's merchant account. The clinic's $1,572 share arrives dripped out weekly, contingent on OpenLoop's own determination that the patient is "active." OpenLoop banks a year of the patient's cash up front; the clinic gets its share on layaway.
04
OpenLoop counts, OpenLoop calculates, the clinic gets what they say. The weekly payment is "based on count of net active patients for the week by Month Cohort," with active status "determined by successful credit card charge," all measured inside systems only OpenLoop can see. The proposal grants no audit rights, no reporting standard, and no recourse if their count and the clinic's disagree. "Net" active also implies refunds and chargebacks are clawed back from the clinic's remittance.
05
OpenLoop sets the refund policy for the clinic's customers. The proposal dictates that patients "may request refund for any reason at any time." A generous refund policy is defensible, but it is imposed unilaterally, on revenue that flows through OpenLoop's account, with the resulting losses netted against the clinic's share. The clinic carries refund exposure on a policy it did not write and cannot change.
06
Reserves and hold-backs on the clinic's revenue. OpenLoop explicitly manages "reserves/hold-backs" on the merchant account. Standard merchant practice, except it is the clinic's patients' payments being reserved, at a percentage and duration the clinic does not control, by a counterparty it cannot audit. Structurally, the clinic is an unsecured creditor of OpenLoop for every dollar in transit.
07
The product can vanish overnight, and that is in writing. "Availability of any given GLP-1 option may change at any time, with no notice." If a patient's medication disappears, OpenLoop will "attempt" to find an alternative, but "not all patients will qualify." The clinic's core offering, the thing its marketing spend acquired patients for, exists at OpenLoop's discretion, and OpenLoop has pre-disclaimed any obligation when it does not.
08
Pricing is a moving target with a signature deadline. The proposal expires in 30 days and states pricing "will change immediately upon changes in FDA and state regulations." Combined with the previous flag, the clinic is asked to sign a 12-month commitment against pricing and product availability that OpenLoop reserves the right to change at any moment.
09
The clinic is asked to sign against blanks. An upfront implementation fee is normal; what sits behind it is not. In OpenLoop's proposal, the provider quantities in Schedule A are literally "TBD," the staff start date is "tbd," and holiday coverage is explicitly excluded, yet $4,500 is due at signature and the 12-month clock starts anyway. The clinic commits to a year against a staffing plan that has not been written. And the scope is deliberately narrow: every future business line triggers "an addendum to the MSA and a separate implementation fee." Expansion is a tollbooth, not a feature.
10
The margins on commodity products are hard to defend. On the sexual-health single-dose 10-pack, the patient pays $119 and the clinic receives $50, so OpenLoop keeps 58% on generic sildenafil or tadalafil that costs roughly a dollar a dose at compounding cost. The clearest example is the biotin supplement: the patient pays $35 a month, the clinic receives $11, and OpenLoop keeps $24 (69%) on an over-the-counter vitamin. These are not clinical-services margins; they are what a captive channel looks like.
11
Coverage and eligibility carve-outs hide behind the "50-state" headline. TRT with scheduled medications is available in only about 35 listed states ("subject to change at any time"). Weight loss is capped at ages 18 to 74, TRT at 25+, sexual health at 21+ with 75+ restricted to single-ingredient products. Staffing "does not include holiday coverage." OpenLoop defines the clinic's addressable market, and reserves the right to redefine it without notice.
12
The proposal does not keep its own numbers straight. The microdosing table lists the 24-week option as "$159/mo (charged as $507)" and the 52-week option as "$149/mo (charged as $507)": the same $507 for both, when the stated monthly rates imply roughly $954 and $1,937 respectively. A pricing document with internally contradictory numbers is either careless or convenient; either way, it is what the contract will incorporate by reference, and the clinic would be the one discovering which figure OpenLoop honors after signing. Note also that TRT care coaching is "$5 per patient per month (waived)": waived, not removed. The right to start charging is retained.
13
"Paid by OpenLoop" means deducted from the clinic. The tables tout "(labs paid by OpenLoop)" in Month 2, and in exactly that month the clinic's remittance drops $12 on semaglutide and $30 on tirzepatide. The "optional" Care Coaching works identically: the care-coaching-included tables carry a footnote confirming a "$10 per 4-week reduction in Admin Fee," and every figure in the clinic's column falls by precisely $10 while OpenLoop's retained share is untouched. Across the entire proposal, not one cost is absorbed on OpenLoop's side of the ledger.
14
The termination clause points one way. "12-month initial term, 30 day notice to terminate for any reason." Read from both sides: if the clinic terminates, it leaves behind its merchant account, card tokens, billing relationships, and patient records, all resident in OpenLoop's systems, and effectively restarts from zero. If OpenLoop terminates, it loses one revenue-share client and keeps everything. A mutual 30-day clause between parties with wildly asymmetric switching costs is not mutual at all.
15
Even the legitimacy credential may be a tether. Before paying the $3,000 for "LegitScript Through OpenLoop Integration," ask in writing: if certification is obtained through OpenLoop's integration, does it survive the clinic's departure from the platform? The proposal is silent.
24
The pattern across all fifteen
OpenLoop holds the cash, the count, the policy, the product availability, the pricing, and the exit. The client holds the brand risk, the marketing cost, the refund exposure, and a 12-month obligation. Tessic Health's flat-fee model does not merely price differently; most of the above cannot happen on it, because Tessic takes no share of the brand's revenue and the client owns the patients, the records, and the data from the first day. Tessic prepares and files the client's LegitScript application as part of setup, and the brand launches on providers, pharmacy, and software that already operate under LegitScript certification.
25
The bottom line: follow the money
OpenLoop's proposal reads well until the money is followed. The clinic pays $4,000 more upfront once LegitScript is included, signs for twelve months against pricing OpenLoop can change at any moment and product availability it can pull "with no notice," surrenders its merchant account, its card tokens, and its patient data pipeline, and then hands over half or more of every maintenance patient's payment, a cut that grows as patients stay longer, to a vendor with an HHS-confirmed 716,000-patient breach, sub-3-star employer ratings, and a 69% margin on a drugstore vitamin. Tessic Health's Launch plan charges $8,000 once with the LegitScript application filed as part of setup, $1,000 flat a month, binds the client to nothing, marks up nothing, and leaves the client owning the patients, the records, the data, and the margin. Year one is $20,000 on Tessic versus $30,000 locked in on OpenLoop, and at 500 maintenance semaglutide patients OpenLoop's retained share alone is $750,000 a year on its own numbers. One platform is built to make money when the client does. The other is built to make money from the client.
26
Where OpenLoop stands out
OpenLoop's retained share does bundle real services: billing, clinical consults, base MWL labs, patient support, and medication cost, delivered by a network that covers all 50 states plus DC. For a program that wants one vendor to hold everything, that bundle is the appeal. It is also the whole problem, because every one of those services is priced as a 50 to 59 percent share of the patient's payment, for as long as the patient stays. On Tessic Health the same consults are a flat $25, medication is wholesale at 0% markup, and labs, billing, and the patient portal sit inside a flat platform fee, so each service OpenLoop folds into its share is a visible flat line and the difference stays with the brand. The brand also holds its own billing relationship, owns its patients and records, launches in days, and can leave any month. OpenLoop's bundle is real. Tessic Health delivers the same bundle without taking a share of it, which makes it the obvious choice for any clinic that bills its own patients.
COMMON QUESTIONS
Questions about OpenLoop and Tessic Health.
OpenLoop's proposal prices implementation at $9,000, split $4,500 at signing and $4,500 at first patient, with expedited LegitScript certification as a $3,000 add-on and a $1,500 monthly fee from the first patient seen, all on a 12-month initial term. The larger cost is the revenue model: on maintenance patients OpenLoop retains roughly 50 to 59 percent of what the patient pays. Tessic Health's equivalent figures, on its Launch plan, are $8,000 once with the LegitScript application filed as part of setup and $1,000 a month, month to month, with no per-patient cut and no revenue share. Tessic also publishes Grow at $2,000 a month with a $15,000 setup, Scale at $4,000 a month with a $25,000 setup, and Tessic Prescribe at custom pricing, all on the same terms.
Structurally, yes. Patients pay into OpenLoop's merchant account, and OpenLoop remits a scheduled amount back to the clinic weekly, keeping the difference. On its own proposal's numbers, a maintenance tirzepatide patient pays $339 a month and the clinic receives $138, so OpenLoop retains $201, about 59 percent, every month the patient stays. Tessic Health takes no revenue share on any plan.
OpenLoop does. Patient payments run through OpenLoop's merchant account, the card tokens live in OpenLoop's systems, and patient records sit in OpenLoop's EHR. Leaving the platform means re-acquiring payment authorization from every patient and rebuilding billing from zero. On Tessic Health, the client owns the brand, the patients, the records, and the data from the first day, and owns the billing relationship; all of it leaves with the client if it cancels.
Yes. On January 7, 2026, an unauthorized third party accessed OpenLoop's systems and exfiltrated files affecting up to 716,000 patients across the telehealth brands running on its platform. The incident is confirmed on the HHS Office for Civil Rights breach portal and was reported to the California and Texas Attorneys General.
It depends on which model the brand wants to be on. OpenLoop bundles clinicians, billing, and fulfillment into a revenue-retention model with a 12-month term. A brand that wants flat published fees, medication at wholesale cost with 0% markup, a $25 consult rate, no term, and ownership of its patients, records, data, and billing relationship is the buyer Tessic Health was built for; the line-by-line math is above.
WHAT TO ASK
Six questions for every partner on the list.
The answers separate a clinic you own from a clinic you rent.
01
Who owns the patients?
Ask whether patients, records, and data leave with you on day one of a cancellation, and what that export looks like in practice.
02
What is the medication margin?
A markup on medication is a hidden revenue share. Ask for the wholesale invoice next to what you are billed.
03
Is there a revenue share?
Percent-of-revenue terms scale against you. Flat platform fees do not.
04
How many states on launch day?
Coverage that fills in over quarters is a launch that happens over quarters. Ask for the licensed count today.
05
Who holds the legal structure?
Ask who owns the professional corporation, who drafts the MSO agreement, and whether it is drafted for your ownership.
06
What is the contract term?
Month-to-month is only offered by partners confident the clinic performs. Multi-year lock-ins say the opposite.
SOURCES
OpenLoop facts checked against public sources as of August 23, 2026. OpenLoop information comes from OpenLoop's "Summary of Proposed Services" (expiring May 28, 2026), the HHS OCR breach portal as reported by SecurityWeek, HIPAA Journal, and Security Affairs (May 2026), and Glassdoor and Indeed company pages (May 2026), as of August 23, 2026; where a figure is not published, it is stated as not publicly listed rather than estimated. Tessic Health fixed-fee figures quote the Launch plan ($1,000 a month, $8,000 setup); Grow, Scale, and Tessic Prescribe are published on the Tessic Health pricing page and carry the same commercial terms. Per-patient figures are OpenLoop's own and exclude shipping; no Tessic Health medication prices or per-patient dollar outcomes are stated on this page. Tessic Health claims restate what tessichealth.com publishes elsewhere. OpenLoop is a trademark of its respective owner, which is not affiliated with Tessic Health and does not endorse this page. Not legal or financial advice; verify contract terms against executed agreements. Offerings and pricing may have changed since review.